A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is below a predetermined amount, the subject is treated as a high-risk patient.

Disclosed herein are compositions and formulations containing a TATk-CDKL5 fusion protein. Also disclosed are methods of producing a TATk-CDKL5 fusion protein from vectors containing a TATk-CDKL5 cDNA and methods of transducing cells with the vectors containing a TATk-CDKL5 cDNA and the TATk-CDKL5 fusion protein

The invention relates to the use of a citrate solution for affinity-chromatographic removal of C-reactive protein (CRP) from biological fluids, wherein the CRP is affinity-chromatographically removed using (Ca.sup.2+-dependent) binding of CRP to a column material functionalized with ?-phosphonooxyalkyl ammonium groups and/or with ?-ammoniumalkoxy-hydroxy-phosphoryloxy groups.

Disclosed herein are compositions and formulations containing a TATk-CDKL5 fusion protein. Also disclosed are methods of producing a TATk-CDKL5 fusion protein from vectors containing a TATk-CDKL5 cDNA and methods of transducing cells with the vectors containing a TATk-CDKL5 cDNA and the TATk-CDKL5 fusion protein.

The present invention provides methods and systems to accurately detect and measure in a biological sample from a patient, endogenous antibodies, e.g., IgA, to inflammatory proteins, which antibodies are useful as diagnostic markers for inflammatory conditions, including bowel disease (IBD), in patients. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

The application provides methods for determining a patient's risk for developing fibrosis or a fibrosis-related disorder. Concentrations of C reactive protein (CRP) and serum amyloid protein (SAP) are measured from a biological sample to determine the SAP-to-CRP ratio. This ratio can then be compared with one or more SAP-to-CRP reference ratios to determine a patient's risk for developing a fibrosis related disorder. The diagnostic methods can also be used to determine the severity of fibrosis in a patient afflicted with such a disease. Furthermore, methods for treating patients having a fibrosis-related disorder are provided. For example, a patient that has a lower SAP-to-CRP ratio than one or more reference values may be treated with an SAP agonist and/or CRP antagonist to treat or prevent a fibrosis disorder. The methods may further comprise determining the R131/H131 polymorphism of FcRIIA as a risk factor for developing fibrosis or a fibrosis-related disorder.

An object of the present invention is to provide a polydimethylsiloxane substrate to which a peptide having an affinity for polydimethylsiloxane (PDMS) is bound; a method for immobilizing a target protein on a polydimethylsiloxane substrate; a peptide having an affinity for PDMS; a polynucleotide encoding a peptide having an affinity for PDMS; and a vector using thereof. A polydimethylsiloxane substrate to which a peptide having an affinity for polydimethylsiloxane is bound, the peptide comprising the following peptide (1a) or (1b), or a fragment thereof: (1a) a peptide comprising an amino acid sequence represented by at least one member selected from the group consisting of SEQ ID NOs: 1 to 9; and (1b) a peptide comprising the amino acid sequence of (1a) in which one or more amino acids are deleted, substituted, and/or added, the peptide having an affinity for polydimethylsiloxane.

Disclosed are a plasmid comprising dxCas9 and a CRP derivative for controlling the expression of a target gene, a recombinant strain transformed with the plasmid, a preparation method therefor, a target gene control system, and a method for controlling the expression of a target gene, wherein the plasmid, recombinant strain, and expression control system according to the present invention can improve the production of high-value-added substances by construction of a system for simultaneously and multiply controlling the expression of target genes.

A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is below a predetermined amount, the subject is treated as a high-risk patient.